Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (CYCC) on July 9, 2019. The report addresses a regulatory notice from The Nasdaq Stock Market LLC regarding the company's compliance with listing standards. Note: The metadata provided lists "Bio Green Med Solution, Inc.", but the filing text explicitly identifies the registrant as Cyclacel Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The report focuses exclusively on stock listing compliance status.
Material Changes
The material change reported is the receipt of a written notice from Nasdaq granting the company an additional 180-day extension to regain compliance with the minimum $1.00 bid price requirement. The company failed to meet the requirement by the initial deadline of July 8, 2019.
Guidance, Outlook, and Risks
- Compliance Plan: The company intends to effect a reverse stock split, if necessary, to cure the deficiency and raise the share price above $1.00.
- Deadline: The new compliance deadline is January 6, 2020.
- Compliance Criteria: To regain compliance, the common stock must close at or above $1.00 per share for a minimum of 10 consecutive business days before the deadline.
- Risk of Delisting: If compliance is not demonstrated by January 6, 2020, Nasdaq will notify the company that its common stock will be delisted. The company retains the right to appeal this determination to a Hearings Panel.
Investor Verification Checklist
- Verify the current trading price of CYCC to assess the likelihood of meeting the $1.00 threshold.
- Monitor for official announcements regarding the execution of a reverse stock split.
- Track the stock's closing price for 10 consecutive business days to confirm compliance status.
- Review the company's capital structure to understand the impact of a potential reverse split on share count and liquidity.